Your Health, We Care
Release date: 2026-01-21 15:48:13 Recommended: 16
Ponatinib is indicated for the treatment of specific types of chronic myeloid leukemia (CML; a type of white blood cell cancer) in patients who no longer benefit from other CML medications or are unable to take these drugs due to side effects.
The approval of this supplemental New Drug Application (sNDA) was based on data from the Phase Ⅱ OPTIC trial (Optimized Ponatinib Therapy in Chronic Myeloid Leukemia) and the 5-year follow-up data from the Phase Ⅱ PACE trial (Efficacy Evaluation of Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia).
The OPTIC trial enrolled patients with chronic-phase chronic myeloid leukemia (CP-CML) who were highly resistant to their prior tyrosine kinase inhibitor (TKI). The majority of these patients (65%) had not achieved a complete hematologic response (CHR) with previous treatments. Among 88 patients treated with the newly approved efficacy-adjusted dosing regimen (initial dose of 45 mg, followed by dose reduction to 15 mg), 42% achieved a BCR-ABL1 international standard (IS) level of ≤1% at 12 months of treatment, which was the primary endpoint of the OPTIC trial. At a median follow-up of 28.5 months, 73% of patients maintained this response.
Among the above trial patients, 13% experienced arterial occlusive events (AOE) of any grade, and 7% experienced grade 3 or higher arterial occlusive events. During clinical treatment, risk factors such as uncontrolled hypertension and diabetes need to be managed. Extreme caution should be exercised when administering the drug to patients with clinically significant uncontrolled cardiovascular diseases that are active or have a confirmed history.
Ponatinib is also indicated for the treatment of specific types of acute lymphoblastic leukemia (ALL; a type of white blood cell cancer) in patients who no longer benefit from other leukemia medications or are unable to take these drugs due to side effects. Ponatinib belongs to a class of medications known as kinase inhibitors. Its mechanism of action is to block the signal transmission of an abnormal protein that instructs cancer cells to proliferate. This helps inhibit the spread of cancer cells.
Ponatinib is available as an oral tablet. It is usually taken once daily, with or without food. Take ponatinib at approximately the same time each day. Follow the instructions on the prescription label carefully, and consult your doctor or pharmacist if you have any questions. Take ponatinib exactly as directed. Do not take more or less than the prescribed dose, or take it more frequently than instructed by your doctor.
Swallow the tablet whole; do not split, chew, or crush it.
Depending on your response to treatment and any side effects you experience, your doctor may need to delay your treatment, adjust your dose, or permanently discontinue your ponatinib therapy. Discuss how you feel during treatment with your doctor. Continue taking ponatinib even if you feel well. Do not stop taking ponatinib without consulting your doctor.
